Ahmedabad-based drugmaker Eris Lifesciences signed an agreement with Bengaluru-based Strides Shasun to acquire its India branded generics business for ₹500 crore. Eris Lifesciences will acquire over 130 brands in the domains of neurology, psychiatry, and gastro, among others, along with employees who form part of the business. The acquired drugs had sales of ₹181 crore in 2016-17.